The efficacy of nirsevimab in infants who remain vulnerable to severe RSV disease during their first or second RSV season has not been directly established and is based on extrapolation of exposure only.

Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website:

Neonate: Administer within 1 week of birth for neonates born shortly before or during the RSV season, ideally during the birth hospitalization. Infant, Child: Administer shortly before the RSV season …

On May 15, 2024, the Public Health Agency of Canada (PHAC) released the National Advisory Committee on Immunization's (NACI) updated guidance on the prevention of respiratory syncytial …

All infants born between October 1,2025 and March 31,2026 are eligible to receive one dose of nirsevimab (Beyfortus®). Infants and children with the following high-risk conditions may also be …

Apr 24, 2023 · "Today is a historical day for RSV prevention as decades of research and development culminate in Canada's approval of the first immunization against RSV disease.

In Canada, RSV causes yearly outbreaks of respiratory illness, usually starting in late fall and running through to early spring. Reinfections with RSV are common, but illness is usually milder with …

If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered.

The BEYFORTUS® product monograph recommends a single 200 mg dose (administered as two 100 mg/1 mL injections at different sites) for all children who remain vulnerable to severe RSV disease …

Beyfortus® (nirsevimab) is a Sanofi product aimed at improving health through innovative vaccine solutions.